FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891635376> ?p ?o ?g. }

• W2891635376 endingPage "7019" @default.
• W2891635376 startingPage "7019" @default.
• W2891635376 abstract "7019 Background: Pts with RR AML have a poor prognosis. BET proteins bind acetylated histone tails, leading to the upregulation of oncogenic target genes; their inhibition can block aberrant transcription in tumor models. ABBV-075 is a pan-BET inhibitor with antitumor activity in vitro and in xenograft models of AML. This 2-part first-in-human study assesses the safety and PK of ABBV-075 at various monotherapy or combination dosing schedules (NCT02391480). In part 1, the recommended phase 2 dose for ABBV-075 monotherapy in pts with solid tumors was identified. Here, we report preliminary data from part 2 in pts with RR AML. Methods: Adult pts with RR AML received daily ABBV-075 as monotherapy (ABBV075-mono) or combined with venetoclax (ABBV075-VEN). The dose-limiting toxicity (DLT) period was 28 d (ABBV075-mono) or 21 d (ABBV075-VEN). Thrombocytopenia was not considered a DLT. Results: As of 1 Jan 2018, 19 pts (median age: 65 y [range, 30–78]; 14 pts had ≥3 prior therapies) were enrolled: 12 pts in ABBV075-mono, 7 in ABBV075-VEN cohorts. Median time on treatment was 39 d (range, 3–213). There were no DLTs; 16 pts experienced AEs. AEs irrespective of causality in > 3 pts were: anemia (11), fatigue (11), dysgeusia (10), nausea (9), diarrhea (7), decreased appetite (7), febrile neutropenia (6), thrombocytopenia (6), and dry mouth, vomiting, contusion, decreased platelet count, decreased weight, hyponatremia, and hemoptysis (4 each). 15 pts had grade ≥3 AEs (anemia [11]); 13 pts had serious AEs (febrile neutropenia [4]). 10 pts died of causes unrelated to ABBV-075, 5/10 pts due to AML progression. In ABBV075-mono cohorts, bone marrow blast count was ≤50% of baseline in 4/11 evaluable pts. 1 pt (female; normal cytogenetics; STAG2 mut) reached complete remission with incomplete hematologic recovery (thrombocytopenia) in cycle 5, still maintained at 8 m from treatment start. At cutoff date, the median overall survival for all pts was 3.2 m, and 4 pts were still in treatment without progression for 1, 6, 20, and 24 w. Enrollment is ongoing. Conclusions: ABBV-075 was well tolerated and showed antileukemic effects in pts with RR AML. Clinical trial information: NCT02391480." @default.
• W2891635376 created "2018-09-27" @default.
• W2891635376 creator A5017574713 @default.
• W2891635376 creator A5028931954 @default.
• W2891635376 creator A5040369089 @default.
• W2891635376 creator A5045732752 @default.
• W2891635376 creator A5055045706 @default.
• W2891635376 creator A5060015628 @default.
• W2891635376 creator A5061865992 @default.
• W2891635376 creator A5062013948 @default.
• W2891635376 creator A5068133376 @default.
• W2891635376 creator A5081099179 @default.
• W2891635376 creator A5090173368 @default.
• W2891635376 date "2018-05-20" @default.
• W2891635376 modified "2023-09-27" @default.
• W2891635376 title "First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data." @default.
• W2891635376 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.7019" @default.
• W2891635376 hasPublicationYear "2018" @default.
• W2891635376 type Work @default.
• W2891635376 sameAs 2891635376 @default.
• W2891635376 citedByCount "12" @default.
• W2891635376 countsByYear W28916353762019 @default.
• W2891635376 countsByYear W28916353762020 @default.
• W2891635376 countsByYear W28916353762021 @default.
• W2891635376 countsByYear W28916353762023 @default.
• W2891635376 crossrefType "journal-article" @default.
• W2891635376 hasAuthorship W2891635376A5017574713 @default.
• W2891635376 hasAuthorship W2891635376A5028931954 @default.
• W2891635376 hasAuthorship W2891635376A5040369089 @default.
• W2891635376 hasAuthorship W2891635376A5045732752 @default.
• W2891635376 hasAuthorship W2891635376A5055045706 @default.
• W2891635376 hasAuthorship W2891635376A5060015628 @default.
• W2891635376 hasAuthorship W2891635376A5061865992 @default.
• W2891635376 hasAuthorship W2891635376A5062013948 @default.
• W2891635376 hasAuthorship W2891635376A5068133376 @default.
• W2891635376 hasAuthorship W2891635376A5081099179 @default.
• W2891635376 hasAuthorship W2891635376A5090173368 @default.
• W2891635376 hasBestOaLocation W28916353762 @default.
• W2891635376 hasConcept C126322002 @default.
• W2891635376 hasConcept C141071460 @default.
• W2891635376 hasConcept C197934379 @default.
• W2891635376 hasConcept C2777054765 @default.
• W2891635376 hasConcept C2777063308 @default.
• W2891635376 hasConcept C2778248108 @default.
• W2891635376 hasConcept C2778850193 @default.
• W2891635376 hasConcept C2780580376 @default.
• W2891635376 hasConcept C29730261 @default.
• W2891635376 hasConcept C71924100 @default.
• W2891635376 hasConcept C90924648 @default.
• W2891635376 hasConceptScore W2891635376C126322002 @default.
• W2891635376 hasConceptScore W2891635376C141071460 @default.
• W2891635376 hasConceptScore W2891635376C197934379 @default.
• W2891635376 hasConceptScore W2891635376C2777054765 @default.
• W2891635376 hasConceptScore W2891635376C2777063308 @default.
• W2891635376 hasConceptScore W2891635376C2778248108 @default.
• W2891635376 hasConceptScore W2891635376C2778850193 @default.
• W2891635376 hasConceptScore W2891635376C2780580376 @default.
• W2891635376 hasConceptScore W2891635376C29730261 @default.
• W2891635376 hasConceptScore W2891635376C71924100 @default.
• W2891635376 hasConceptScore W2891635376C90924648 @default.
• W2891635376 hasIssue "15_suppl" @default.
• W2891635376 hasLocation W28916353761 @default.
• W2891635376 hasLocation W28916353762 @default.
• W2891635376 hasOpenAccess W2891635376 @default.
• W2891635376 hasPrimaryLocation W28916353761 @default.
• W2891635376 hasRelatedWork W1583687693 @default.
• W2891635376 hasRelatedWork W1821802350 @default.
• W2891635376 hasRelatedWork W1938895800 @default.
• W2891635376 hasRelatedWork W2004489722 @default.
• W2891635376 hasRelatedWork W2243375749 @default.
• W2891635376 hasRelatedWork W2488017628 @default.
• W2891635376 hasRelatedWork W2520952934 @default.
• W2891635376 hasRelatedWork W2590098288 @default.
• W2891635376 hasRelatedWork W4231279047 @default.
• W2891635376 hasRelatedWork W4296848301 @default.
• W2891635376 hasVolume "36" @default.
• W2891635376 isParatext "false" @default.
• W2891635376 isRetracted "false" @default.
• W2891635376 magId "2891635376" @default.
• W2891635376 workType "article" @default.